| 【Fixed Income Research】INDYIJs: still offers decent risk-return profile |
| 【Company Research】InnoCare Pharma (9969 HK) – Strong sales of orelabrutinib in 1H22 |
| 【Company Research】Ming Yuan Cloud (909 HK) – Weak SaaS demand with tighter cost control ahead |
| 【Sector Research】China Banking Sector – Banks’ asset quality remained stable in 2Q22; LPR cut in line with market expectations |
| 【Company Research】Kingdee (268 HK) – Cloud on track with improved earnings quality |
| 【Company Research】Jahwa (600315 CH) – 2Q miss; but the worst is likely behind us |
| 【Company Research】Shennan Circuits (002916 CH) – 3Q could be lower despite satisfactory 2Q results |
| 【Company Research】China Lilang (1234 HK) – Resilient given pandemic plus decent yield |
| 【Company Research】Kindly Medical (1501 HK) – Solid growth demonstrates a rapid recovery from COVID |
| 【Company Research】PA Good Doctor (1833 HK) – Early achievements of Strategy 2.0 |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
